Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)

NCT00862342 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Bevacizumab (Avastin)

Sponsor

Asan Medical Center